Ranbaxy launches India’s first biosimilar of Infliximab

Ranbaxy Laboratories announced the launch of Infimab (BOW015), the first Remicade (Infliximab) biosimilar in India


(Photo Courtesy: www.printwand.com)

Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai.

The product was launched at the Indian Rheumatology Association Conference (IRACON), in the presence of thousands of rheumatologists and doctors from around the country.

Infimab is being introduced to the Indian market through a licensing partnership with EPIRUS Biopharmaceuticals, a US and Swiss-based focused on the global development and commercialization of biosimilar monoclonal antibodies.

The innovator reference product is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis (RA), Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.

Infimab marks Ranbaxy's entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email